Endothelial lipase genetic polymorphisms and the lipid-lowering response in patients with coronary artery disease on rosuvastatin

• Published in: Lipids in health and disease Vol. 15; no. 1; p. 148
• Main Authors: Cai, Gaojun, Zhang, Bifeng, Shi, Ganwei, Weng, Weijin, Yang, Liping, Xue, Sheliang
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 06-09-2016; BioMed Central
• Subjects: Adult; Aged; Aged, 80 and over; Asian Continental Ancestry Group; Care and treatment; Cholesterol, HDL - blood; Cholesterol, LDL - blood; Complications and side effects; Coronary Artery Disease - blood; Coronary Artery Disease - drug therapy; Coronary Artery Disease - genetics; Coronary Artery Disease - pathology; Coronary heart disease; Female; Genetic aspects; Genetic polymorphisms; Genotype; Health aspects; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage; Lipase - genetics; Male; Middle Aged; Morbidity; Polymorphism, Genetic; Risk factors; Rosuvastatin; Rosuvastatin Calcium - administration & dosage; Triglycerides - blood; Endothelial lipase; Rosuvastatin; Single nucleotide polymorphism; Coronary artery disease
• ISSN: 1476-511X; 1476-511X
• DOI: 10.1186/s12944-016-0295-3

Endothelial lipase (EL) plays an important role in the regulation of lipid metabolism by reducing the high density lipoprotein cholesterol (HDL-C) levels and inducing the macrophages to take up native low density lipoprotein cholesterol (LDL-C). Our purpose was to investigate the impact of EL genetic polymorphisms on the lipid-lowering effects of rosuvastatin in Chinese coronary artery disease (CAD) patients.
One hundred twenty-one unrelated CAD patients, who underwent the treatment with rosuvastatin (10mg/day) for four to eight weeks, were enrolled in this study. Before and after treatment, serum lipids levels were measured. Genotypes of EL 2037T/C and 2237 G/A polymorphisms were detected by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method.
Patients with EL 2037C allele (CC + CT) had significantly lower LDL-C levels than those with TT genotype (CC + CT: 2.60 ± 0.74 mmol/l; TT: 2.90 ± 0.87 mmol/l; P = 0.047), before rosuvastatin treatment. No significant differences between baseline lipid levels and the EL 2237G/A genotypes were observed. After treatment with rosuvastatin, total cholesterol (TC), high triglyceride (TG) and LDL-C levels decreased from baseline, on average, by 23.09 % (4.59 ± 0.96 mmol/l to 3.47 ± 0.83 mmol/l), 6.36 % (2.01 ± 1.18 mmol/l to 1.68 ± 1.16 mmol/l), 32.48 % (2.77 ± 0.83 mmol/l to 1.79 ± 0.62 mmol/l), respectively (all P < 0.05) in all patients. While changes in HDL-C levels did not reach statistical significance. No significant effects of EL 2037T/C or 2237G/A polymorphism were observed on lipid-lowering effects of rosuvastatin.
EL 2037T/C and 2237 G/A polymorphisms might not affect the lipid-owing effects of rosuvastatin in Chinese CAD patients.